DYRK3 and melanoma: Our data suggest that DYRK3 directly phosphorylates p62 at Thr-269, stimulating the activation of the mTORC1-mediated downstream signaling pathway and ultimately leading to an increase in the oncogenic function of p62 in melanoma.